<DOC>
	<DOCNO>NCT02730481</DOCNO>
	<brief_summary>This multicenter , open-label , safety study . Eligible subject adult advance malignancy . The study include pretreatment treatment phase . The pretreatment phase consist screen baseline period . The treatment phase consist 4-week treatment period follow-up period .</brief_summary>
	<brief_title>A Study Evaluate Safety , Tolerability , MTD , PK , Activity Oraxol Subjects w Adv . Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>1 . Signed write informed consent 2 . ≥18 year age 3 . Histologically cytologically confirm solid tumor metastatic unresectable standard curative palliative measure exist longer effective 4 . Measurable disease per RECIST v1.1 criterion 5 . Adequate hematologic status demonstrate require transfusion support granulocytecolony stimulate factor ( GCSF ) maintain : ANC ≥1500 cells/mm3 , Platelet count ≥100 x 109/L , Hemoglobin ≥10 g/dL 6 . Adequate liver function demonstrate : Total bilirubin ≤1.5 mg/dL ≤2.0 mg/dL subject liver metastasis , Alanine aminotransferase ≤3 x upper limit normal ( ULN ) ≤5 x ULN liver metastasis present , Alkaline phosphatase ≤3 x ULN ≤5 x ULN bone liver metastasis present 7 . Adequate renal function demonstrate serum creatinine ≤1.5 x ULN creatinine clearance calculation ≥60 mL/min calculate Cockcroft Gault formula 8 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 9 . Life expectancy least 3 month 10 . Women must postmenopausal ( &gt; 12 month without menses ) surgically sterile ( ie , hysterectomy and/or bilateral oophorectomy ) must use effective contraception ( ie , oral contraceptive , intrauterine device , double barrier method condom spermicide ) agree continue use contraception 30 day last dose study drug . 11 . Sexually active male subject must use barrier method contraception study agree continue use male contraception least 30 day last dose study drug . 1 . Have recover ≤ Grade 1 toxicity previous anticancer treatment previous investigational product ( IPs ) 2 . Received IPs within 14 day 5 halflives first study dose day , whichever longer 3 . Are currently receive medication radiation intend treatment malignancy 4 . Women childbearing potential pregnant breastfeed 5 . Currently take concomitant medication 6 . Require therapeutic use anticoagulation medication 7 . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , myocardial infarction within last 6 month , unstable angina pectoris , cardiac arrhythmia , chronic pulmonary disease require oxygen , know bleeding disorder , concomitant illness social situation would limit compliance study requirement 8 . Major surgery upper gastrointestinal ( GI ) tract , history GI disease medical condition , opinion investigator may interfere oral drug absorption 9 . History hypersensitivity paclitaxel , attribute hypersensitivity type reaction Cremophor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>